Lee Y, Kim JW, Nyasae M, et al. GLS1 as a metabolic checkpoint for NASH progression.Hepatology. 2021;74(5):2487-2502. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Prospective study of outcomes in nonalcohol...
Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93(11_suppl_1). Lee Y, Kim JW, Nyasae M, et al. GLS1 as a metabolic checkpoint for NASH progression. Hepatology. 2021;74(5):2487-2502. Sanyal AJ, Friedman SL, M...
Prof. Reeves: The thing is that the patients who develop NASH-associated HCC are older patients with metabolic syndrome. They are obese. They often have type 2 diabetes. They are often treated with insulin, for example....
Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69, 896–904 (2018). 2.Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018). 3.Chitturi, S. et al. The Asia–...
非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)是目前最常见的慢性肝病之一,指除酒精和其他对肝脏有明确损害因素所引起的,肝脏内脂质过度沉积的疾病,包括单纯性脂肪肝(nonalcoholic fatty liver, NAFL)、非酒精性脂肪性肝炎(nonalcoholic steatohepatitis, NASH)及相关肝硬化。其中,NASH是NAFLD恶化的关键...
1.Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan,Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69,896–904 (2018). 2.Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver...
10. Saponaro, F., Sestito, S., Runfola, M., Rapposelli, S. & Chiellini, G. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. Frontiers in Medicine vol. 7 Preprint at https://doi.org/10.3389/fmed....
NASH是一种与肥胖、2型糖尿病和代谢综合征等疾病密切相关的肝脏疾病。它是一种非酒精性脂肪肝病（Non-Alcoholic Fatty Liver Disease，NAFLD）的进展形式，其特征是肝脏脂肪积累和炎症反应，可导致肝脏组织的损害和纤维化。如果不加以控制和治疗，NASH可能会进展为肝硬化和肝癌等严重并发症。什么人容易患上NAFLD或NASH...
3月15日凌晨，全球首个治疗代谢功能障碍相关脂肪性肝炎（MASH，曾称为NASH）成人患者的药物Rezdiffra获得美国食品药品监督管理局（FDA）批准上市！这是一个具有里程碑意义的行业大事件！在此之前，MASH治疗药物领域长期处于一片空白的状态，MASH患者群体基本上无药可用。Resmetirom是一种靶向肝脏的甲状腺激素受体 β（...
1. Targeted therapeutics and novel signaling pathways in non alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) 2. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease 3. Targeting fibrosis: mech...